Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:IMRA NASDAQ:OCUL NASDAQ:RIGL NASDAQ:SPPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$6.88-2.7%$7.63$6.10▼$28.67$476.85M1.41312,566 shs174,291 shsIMRAIMARA$37.96+3.2%$17.12$0.97▼$6.32$995.84M1.09138,364 shs7,279 shsOCULOcular Therapeutix$12.49-2.5%$12.03$5.78▼$13.85$2.18B1.51.85 million shs1.49 million shsRIGLRigel Pharmaceuticals$37.51-1.2%$30.15$13.37▼$43.72$672.93M1.26332,729 shs516,320 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%-1.26%-4.97%-12.06%-73.83%IMRAIMARA0.00%+7.14%-2.97%-22.69%+500.63%OCULOcular Therapeutix0.00%-5.81%+1.51%+46.40%+42.33%RIGLRigel Pharmaceuticals0.00%-8.18%-3.92%+85.81%+177.08%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$6.88-2.7%$7.63$6.10▼$28.67$476.85M1.41312,566 shs174,291 shsIMRAIMARA$37.96+3.2%$17.12$0.97▼$6.32$995.84M1.09138,364 shs7,279 shsOCULOcular Therapeutix$12.49-2.5%$12.03$5.78▼$13.85$2.18B1.51.85 million shs1.49 million shsRIGLRigel Pharmaceuticals$37.51-1.2%$30.15$13.37▼$43.72$672.93M1.26332,729 shs516,320 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%-1.26%-4.97%-12.06%-73.83%IMRAIMARA0.00%+7.14%-2.97%-22.69%+500.63%OCULOcular Therapeutix0.00%-5.81%+1.51%+46.40%+42.33%RIGLRigel Pharmaceuticals0.00%-8.18%-3.92%+85.81%+177.08%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.67Moderate Buy$22.22223.00% UpsideIMRAIMARA 0.00N/AN/AN/AOCULOcular Therapeutix 3.00Buy$17.8342.84% UpsideRIGLRigel Pharmaceuticals 2.40Hold$38.201.85% UpsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SPPI, IMRA, OCUL, BCYC, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025OCULOcular TherapeutixChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.008/12/2025BCYCBicycle TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$22.00 ➝ $10.008/12/2025BCYCBicycle TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$17.00 ➝ $13.008/11/2025BCYCBicycle TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$27.008/11/2025BCYCBicycle TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$48.00 ➝ $44.008/6/2025OCULOcular TherapeutixScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Outperform$22.00 ➝ $20.008/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $32.008/5/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.007/17/2025BCYCBicycle TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$32.00 ➝ $25.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$35.28M13.52N/AN/A$11.48 per share0.60IMRAIMARAN/AN/A$0.50 per share75.24$3.44 per shareN/AOCULOcular Therapeutix$63.72M34.09N/AN/A$2.01 per share6.21RIGLRigel Pharmaceuticals$179.28M3.75$1.07 per share35.19$0.19 per share197.39SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$169.03M-$3.51N/AN/AN/A-1,257.00%-32.43%-26.80%10/30/2025 (Estimated)IMRAIMARA$1.49M$0.05759.35∞N/AN/A2.12%2.00%N/AOCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$5.416.9335.72N/A36.51%438.89%57.03%11/6/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ALatest SPPI, IMRA, OCUL, BCYC, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025BCYCBicycle Therapeutics-$0.95-$1.14-$0.19-$1.14$9.43 million$2.90 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/AIMRAIMARAN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A10.3910.39IMRAIMARAN/A48.9848.98OCULOcular Therapeutix0.2310.1010.02RIGLRigel Pharmaceuticals0.462.021.90SPPISpectrum PharmaceuticalsN/A2.712.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%IMRAIMARA49.28%OCULOcular Therapeutix59.21%RIGLRigel Pharmaceuticals66.23%SPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%IMRAIMARA37.30%OCULOcular Therapeutix2.30%RIGLRigel Pharmaceuticals9.04%SPPISpectrum Pharmaceuticals2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.31 million63.42 millionOptionableIMRAIMARA4126.23 million16.45 millionNot OptionableOCULOcular Therapeutix230173.99 million169.99 millionOptionableRIGLRigel Pharmaceuticals16017.94 million16.32 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableSPPI, IMRA, OCUL, BCYC, and RIGL HeadlinesRecent News About These CompaniesSPECTRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmSeptember 15 at 7:17 AM | globenewswire.comSpectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPISeptember 15 at 3:39 AM | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 15 at 2:34 AM | prnewswire.comDEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025September 12 at 12:01 PM | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 10, 2025 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPISeptember 10, 2025 | globenewswire.comSPECTRUM PHARMACEUTICALS (NASDAQ: SPPI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Class Action by September 24, 2025September 8, 2025 | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPISeptember 5, 2025 | globenewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 5, 2025 | prnewswire.comSpectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPISeptember 2, 2025 | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 2, 2025 | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitAugust 29, 2025 | prnewswire.comROSEN, A RANKED AND LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPIAugust 27, 2025 | globenewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitAugust 26, 2025 | prnewswire.comSPPI New Lead Plaintiff Deadline: Contact Robbins LLP for Information About Leading the Class Action Against SPPIAugust 26, 2025 | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPIAugust 25, 2025 | markets.businessinsider.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure ...August 25, 2025 | bakersfield.comBNASDAQ: SPPI DEADLINE REMINDER: Berger Montague Reminds Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors of Important Class Action Lawsuit DeadlineAugust 25, 2025 | prnewswire.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Spectrum Pharmaceuticals, Inc. ...August 24, 2025 | gurufocus.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPIAugust 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPPI, IMRA, OCUL, BCYC, and RIGL Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$6.88 -0.19 (-2.69%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.IMARA NASDAQ:IMRAIMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Ocular Therapeutix NASDAQ:OCUL$12.48 -0.33 (-2.54%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Rigel Pharmaceuticals NASDAQ:RIGL$37.51 -0.46 (-1.20%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
